查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2004724

药物研发外包市场：2026年至2032年全球市场预测（依服务类型、药物研发阶段、工作流程、药物类型、应用领域及最终用户划分）

Drug Discovery Outsourcing Market by Service Type, Discovery Phase, Workflow, Drug Type, Application Area, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，药物研发外包市场价值将达到 42.9 亿美元，到 2026 年将成长至 46.5 亿美元，到 2032 年将达到 77.1 亿美元，复合年增长率为 8.71%。

主要市场统计数据
基准年 2025 42.9亿美元
预计年份：2026年 46.5亿美元
预测年份：2032年 77.1亿美元
复合年增长率 (%) 8.71%

重组后的药物研发外包生态系统的背景讯息，该生态系统由技术融合、战略伙伴关係和业务永续营运所塑造。

全球药物研发格局正经历着结构性变革时期，其驱动力包括技术飞跃、赞助商优先事项的转变以及不断变化的经济压力。外包已成为製药和生物技术公司利用内部不易获得的专业知识、加快研发进度、快速获得专业能力、管理研发风险以及控制营运成本的核心策略工具。拥有深厚生物学专业知识、合成化学能力和先进资料管理技能的外部供应商，正日益被视为转化研究合作伙伴，而不仅仅是供应商。

人工智慧整合、自动化实验平台、模组化合作伙伴关係、供应链弹性以及监管参与正在如何重塑您的外包策略？

近年来，我们见证了一系列变革性变化，这些变化正在重新定义药物研发外包的框架，并改变申办者评估外部合作伙伴的方式。首先，人工智慧和先进分析技术融入先导化合物的识别和优化工作流程，正在加速假设的生成，实现化合物库的虚拟筛选，并优先进行资讯价值更高的实验。这种变化不仅仅关乎速度，它从根本上改变了药物研发专案的设计，使实验更具针对性，资源分配更加有效率。

本分析检视了 2025 年美国关税变化对供应链、采购实务和外包连续性的多层次营运影响。

2025年推出的政策变革和贸易措施为依赖跨境供应链获取试剂、仪器和中间体化合物的机构带来了切实的营运挑战。影响某些实验室耗材、特殊化学品和部分仪器组件的关税调整增加了整体成本，并导致关键投入品的前置作业时间出现波动。对许多赞助商和供应商而言，最直接的影响是需要修订采购计画和供应商协议，以降低关税波动和运输中断的风险。

为了促进与供应商的合作，我们透过绘製服务类型、药物发现阶段、工作流程、药物模式、治疗应用和最终用户趋势图，创建了详细的见解。

服务类型细分揭示了赞助商在哪些方面集中投入外包成本和预期收益。根据服务类型，市场被分为三大类：生物服务、化学服务和资料管理服务。生物服务进一步细分为检测方法开发和生物测试，反映了对稳健的转化型检测方法以及体外/体内测试能力的需求。化学服务进一步细分为客製化合成和製程研发，凸显了对客製化化学解决方案和可扩展合成通路开发的持续需求。资料管理服务进一步细分为生物资讯学和资料整合，强调整合多体学和筛检资料的能力如今已成为服务提供者的竞争优势。

对美洲、欧洲、中东和非洲以及亚太地区如何以独特的方式影响外包合作伙伴的选择和业务策略进行区域分析。

区域趋势影响策略外包的选择，每个区域都有其独特的驱动因素和限制因素。在生物技术创新中心和创业投资专案集中的美洲地区，由于需要快速且灵活的伙伴关係模式，整合药物研发服务和先进资料分析能力的需求仍然强劲。在此背景下，拥有深厚的治疗专业知识、强大的数据平台和丰富的监管经验的供应商往往是快速开发专案的首选合作伙伴。

关键企业级趋势表明，整合平台、专家伙伴关係和卓越的合规性如何决定竞争差异化和客户偏好。

企业层面的竞争格局日益取决于企业整合跨学科能力并维持高品质标准和合规性的能力。领先的合约研究组织 (CRO) 和专业供应商正透过投资专有平台、与科技公司建立策略合作伙伴关係以及在小分子和生物製药项目方面积累的丰富经验来脱颖而出。拥有内部计算科学团队和检验的生物资讯流程的公司能够提供更具预测性的决策支援并缩短迭代周期。

领导者用来优化供应商韧性、资料互通性、合约柔软性、监管合规性和技术合格的实用建议。

产业领导者可以采取以下几个切实可行的步骤来增强其外包能力，并从外部伙伴关係中获得更大价值。首先，透过对多家供应商进行关键能力认证，并制定紧急时应对计画以减少对单一供应商的依赖，从而实现供应商生态系统的多元化。这种方法可以在不牺牲专业方法取得的前提下提高韧性。其次，投资于可互通的资料标准和安全的云端架构，以实现委託方和外部实验室之间的无缝交接，从而减少返工并加快决策速度。

采用严谨的混合方法研究途径，结合高阶主管的访谈、二手技术审查、能力映射和情境分析，得出可操作的见解。

本概要的研究结合了定性和定量方法，以确保得出可靠且令人信服的见解。主要研究包括对赞助机构和服务供应商的高级研发主管、采购经理和技术经理进行结构化访谈，以收集关于能力需求、供应商选择标准和区域营运限制的第一手观点。此外，也咨询了监管事务专家和供应链专家，以分析政策和物流方面的影响。

简洁的结论强调，科学的严谨性、全面的资料系统和策略性的风险管理对于外包药物研发专案的成功至关重要。

总而言之，药物研发外包环境正日趋成熟，成为一个更加一体化、数据驱动的生态系统，其中战略伙伴关係的选择对专案进度和科研成果有着显着影响。计算化学、自动化检测系统和数据整合技术的进步，使得能够提供可重复、可解释的数据集，并将输出结果转化为清晰的后续实验步骤的供应商变得愈发重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 药物研发外包市场：依服务类型划分

  • 生物服务
    • 检测方法开发
    • 生物学检查
  • 化学服务
    • 客製合成
    • 製程研究与开发
  • 资料管理服务
    • 生物资讯学
    • 数据集成

第九章 药物研发外包市场：依药物研发阶段划分

  • 先导药物最适化
    • 化合物筛检
    • 基于结构的药物发现
  • 目标识别
    • 生物标誌物生成
    • 基因组定序方法

第十章 药物研发外包市场：依工作流程划分

  • 先导化合物筛选及候选化合物优化
  • 临床前开发
  • 目标识别和筛检
  • 目标检验和功能资讯学

第十一章 药物研发外包市场：依药物类型划分

  • 聚合物化合物
    • 生技药品
    • 生物相似药
  • 小分子药物

第十二章 药物研发外包市场：依应用领域划分

  • 心血管疾病
    • 心臟衰竭
    • 高血压
  • 感染疾病
    • 细菌感染疾病
    • 病毒感染疾病
  • 肿瘤学
    • 骨髓恶性肿瘤
    • 固体癌

第十三章 药物研发外包市场：依最终用户划分

  • 合约研究组织（CRO）
    • 全方位CRO服务
    • 专业合约研究组织
  • 製药和生物技术公司
    • 大公司
    • 小型企业
  • 研究机构
    • 学术机构
    • 政府附属研究机构

第十四章 药物研发外包市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 药物研发外包市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 药物研发外包市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国药物研发外包市场

第十八章：中国的药物研发外包市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies Inc.
  • Aragen Life Sciences Ltd.
  • BPS Bioscience, Inc.
  • Celentyx Ltd.
  • Charles River Laboratories International, Inc.
  • Covance, Inc.
  • Crown Bioscience, Inc.
  • Curia Global, Inc.
  • Dalton Pharma Services
  • Eurofins Scientific
  • Evotec SE
  • Explicyte
  • GenScript BIoTech Corporation
  • HD Biosciences Co., Ltd.
  • IQVIA
  • Jubilant Biosys Ltd.
  • Laboratory Corporation of America Holdings
  • Merck & Co., Inc.
  • Oncodesign Services
  • Personalis, Inc.
  • Pfizer Inc.
  • PPD Inc.
  • Promega Corporation
  • Revvity Discovery Limited
  • Sanofi SA
  • STC Biologics Inc.
  • Syngene International Ltd.
  • TCG Lifesciences Pvt. Limited
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-742BD517D92E

The Drug Discovery Outsourcing Market was valued at USD 4.29 billion in 2025 and is projected to grow to USD 4.65 billion in 2026, with a CAGR of 8.71%, reaching USD 7.71 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.29 billion
Estimated Year [2026] USD 4.65 billion
Forecast Year [2032] USD 7.71 billion
CAGR (%) 8.71%

Contextual introduction to the reshaped drug discovery outsourcing ecosystem shaped by technology convergence, strategic partnerships, and operational resilience

The global drug discovery environment is undergoing a period of structural change driven by technological breakthroughs, evolving sponsor priorities, and shifting economic pressures. Outsourcing has become a core strategic lever for pharmaceutical and biotechnology organizations to access specialized capabilities rapidly, manage development risk, and control operational costs while accelerating timelines through expertise not readily available in-house. External providers that combine deep biological expertise, synthetic chemistry capabilities, and advanced data management are increasingly viewed as partners in translational research rather than simple vendors.

Concurrently, the rise of machine learning, cloud-native informatics, and high-content screening platforms has altered expectations around data interoperability and decision velocity. Sponsors now prioritize partners who can ingest heterogeneous data streams, apply robust analytic pipelines, and translate outputs into clear experimental next steps. This shift favors integrated service models that bridge wet-lab proficiency with computational workflows. Moreover, the complexity of modern modalities-ranging from engineered biologics to precision small molecules-places a premium on CROs and specialty service firms that demonstrate regulatory acumen and scalable operational practices.

As organizations balance the need for innovation with tighter procurement scrutiny and supply chain resilience concerns, outsourcing choices hinge on flexibility, quality, and the ability to co-develop programs across discovery phases. The remainder of this summary outlines the most consequential forces reshaping outsourcing strategies and offers pragmatic guidance for leaders navigating this transformed environment.

How AI integration, automated laboratory platforms, modular partnering, supply chain resilience, and regulatory engagement are reshaping outsourcing strategies

Recent years have seen a series of transformative shifts that are redefining the contours of drug discovery outsourcing and changing how sponsors evaluate external partners. First, the integration of AI and advanced analytics into lead identification and optimization workflows is accelerating hypothesis generation, enabling virtual triage of compound libraries and prioritizing experiments that yield higher informational value. This change is not merely about speed; it is about altering the design of discovery programs so that experiments are more targeted and resource allocation is more efficient.

Second, the parallel advancement of laboratory automation and miniaturized assays has expanded throughput while improving reproducibility. This technological progression allows service providers to offer scalable assay cascades that feed richer, more standardized data into informatics platforms. Third, the industry has embraced modular business models in which sponsors combine full-service CRO relationships with boutique specialist engagements to access niche capabilities without sacrificing program continuity.

Fourth, supply chain resiliency and geopolitical factors have prompted many organizations to reconsider sourcing strategies, resulting in increased interest in regional capacity and single-source risk mitigation. Finally, regulatory authorities are engaging earlier in development conversations around complex modalities and biomarker-driven programs, which raises the bar for outsourced partners to demonstrate methodological rigor, traceability, and compliance. Together, these shifts are producing a landscape where capability depth, data integration, and strategic alignment determine long-term partnership value.

Analyzing the layered operational consequences of the United States tariff changes in 2025 on supply chains, procurement practices, and outsourcing continuity

Policy changes and trade measures introduced in 2025 have introduced tangible operational considerations for organizations that rely on cross-border supply chains for reagents, instrumentation, and intermediate compounds. Tariff adjustments affecting certain classes of laboratory consumables, specialized chemicals, and selected instrumentation components have increased landed costs and introduced variability in lead times for critical inputs. For many sponsors and providers, the immediate consequence has been a re-evaluation of sourcing maps and vendor contracts to reduce exposure to tariff volatility and shipping disruptions.

In practical terms, some discovery groups have accelerated qualification of secondary suppliers and moved to dual-sourcing strategies to maintain experimental continuity. Others have prioritized vendor partnerships that include local inventory stocking or regional manufacturing capabilities to limit the impact of import duties and customs delays. Contractual clauses related to price pass-through, force majeure, and delivery SLAs have become focal points during procurement negotiations, reflecting the need to allocate risk explicitly.

Operational teams are also adjusting project timelines and buffer inventories where possible to accommodate intermittent delays, while finance and procurement functions are recalibrating budgeting assumptions to account for higher variable input costs. Importantly, the tariff-driven pressures are reinforcing pre-existing strategic trends toward regionalization and nearshoring for certain high-volume or time-sensitive processes, without necessarily undoing the advantages of global capability networks that are required for specialized technologies and rare expertise.

Granular segmentation-driven insights that map service types, discovery phases, workflows, drug modalities, therapeutic applications, and end-user dynamics for vendor alignment

Service-type segmentation reveals where sponsors are concentrating their outsourcing spend and expectations. Based on Service Type, the market is studied across Biological Services, Chemical Services, and Data Management Services. The Biological Services is further studied across Assay Development and Biological Testing, reflecting demand for robust, translatable assays and in vitro/in vivo testing capacities. The Chemical Services is further studied across Custom Synthesis and Process R&D, highlighting the continued need for bespoke chemistry solutions and scalable route development. The Data Management Services is further studied across Bioinformatics and Data Integration, underscoring that the ability to harmonize multi-omic and screening data is now a competitive differentiator for providers.

Discovery-phase segmentation clarifies where specialized competencies matter most during program progression. Based on Discovery Phase, the market is studied across Lead Optimization and Target Identification. The Lead Optimization is further studied across Compound Screening and Structure-Based Drug Design, indicating a focus on iterative chemotype refinement and computationally guided selection. The Target Identification is further studied across Biomarker Discovery and Genomic Sequencing Methods, reflecting investments in molecular characterization and patient-stratified approaches.

Workflow-focused segmentation maps capabilities to program milestones. Based on Workflow, the market is studied across Lead Identification & Candidate Optimization, Preclinical Development, Target Identification & Screening, and Target Validation & Functional Informatics, which helps sponsors align provider skill sets to project phases. Drug-type segmentation separates modality-specific requirements. Based on Drug Type, the market is studied across Large Molecules and Small Molecules. The Large Molecules is further studied across Biologics and Biosimilar, indicating divergence in analytical demands and manufacturing pathways. Application-area segmentation aligns therapeutic focus with technical needs. Based on Application Area, the market is studied across Cardiovascular Diseases, Infectious Diseases, and Oncology. The Cardiovascular Diseases is further studied across Heart Failure and Hypertension. The Infectious Diseases is further studied across Bacterial Infections and Viral Infections. The Oncology is further studied across Hematological Malignancies and Solid Tumors, emphasizing the need for disease-specific assay suites. End-user segmentation clarifies channel dynamics and decision drivers. Based on End User, market is studied across Contract Research Organizations, Pharmaceutical & Biotechnology Companies, and Research Institutes. The Contract Research Organizations is further studied across Full-Service CROs and Specialty CROs. The Pharmaceutical & Biotechnology Companies is further studied across Large Enterprises and SMEs. The Research Institutes is further studied across Academic Institutions and Government Research Centers, which affects procurement cycles and collaboration incentives.

These segmentation lenses collectively provide a granular way to evaluate provider fit for discrete program requirements, enabling sponsors to match service scope, technological depth, and regulatory alignment to the specific stage and therapeutic focus of their projects.

Regional intelligence on how Americas, Europe Middle East & Africa, and Asia-Pacific each distinctively influence outsourcing partner selection and operational strategies

Regional dynamics are shaping strategic choices for outsourcing, with distinct drivers and constraints in each geography. Americas continue to exhibit strong demand for integrated discovery services and advanced data analytics capabilities, driven by a concentration of biotech innovation hubs and venture-backed programs that demand speed and flexible partnership models. In this context, providers that combine deep therapeutic expertise with robust data platforms and regulatory familiarity tend to be preferred partners for fast-moving development programs.

Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization and access to specialized translational centers support collaboration across borders, while localized capacity and talent pools differ markedly between Western and emerging markets. Sponsors operating in this region emphasize rigorous compliance frameworks and provenance for biological materials, along with collaborative arrangements that bridge academic innovation and industrial development.

Asia-Pacific remains a focal point for both cost-efficient laboratory services and rapidly maturing centers of scientific excellence, particularly in biologics, synthetic chemistry, and high-throughput screening. Investments in regional manufacturing capacity and local regulatory pathways are reducing friction for programs that require scale and speed in late-stage preclinical work. Across all regions, the interplay between local capabilities, regulatory expectations, and supply chain resilience informs partner selection and contracting models.

Key company-level dynamics showing how integrated platforms, specialist partnerships, and compliance excellence determine competitive differentiation and client preference

Company-level competitive dynamics are increasingly defined by the ability to integrate cross-disciplinary capabilities while maintaining high standards of quality and compliance. Leading contract research organizations and specialty providers differentiate themselves through investments in proprietary platforms, strategic alliances with technology firms, and demonstrated experience across both small molecule and biologics programs. Firms with embedded computational teams and validated bioinformatics pipelines are able to offer more predictive decision support and shorter iteration cycles.

Partnership models matter: full-service providers that can manage end-to-end discovery workflows retain appeal for sponsors seeking program continuity, whereas specialty CROs remain essential for complex assays, custom chemistry, and novel modality expertise. Collaboration between larger integrators and niche specialists is a common pattern, where the larger firm coordinates program delivery while the specialist contributes critical technical depth. Additionally, companies that emphasize transparent quality systems, traceable data management practices, and clear regulatory documentation have a competitive advantage when supporting translational or biomarker-driven programs.

Strategic moves such as platform licensing, geographic expansion, and co-investment in localized manufacturing or reagent supply chains are practical ways companies are responding to client needs. Ultimately, vendor selection reflects a trade-off between breadth of services, depth of technical competence, and the ability to align commercial terms to program risk and timelines.

Actionable recommendations for leaders to optimize supplier resilience, data interoperability, contracting flexibility, regulatory alignment, and technology qualification

Industry leaders can take several pragmatic steps to strengthen their outsourcing posture and extract greater value from external partnerships. First, diversify supplier ecosystems by qualifying multiple providers for critical capabilities and establishing contingency plans that reduce single-source exposure. This approach improves resilience without sacrificing access to specialized methods. Second, invest in interoperable data standards and secure cloud architectures that allow seamless handoffs between sponsors and external laboratories, thereby reducing rework and accelerating decision-making.

Third, adopt flexible contracting frameworks that align incentives across milestones and allow scope adjustments as scientific hypotheses evolve. Such models can include phased engagements with clear go/no-go criteria and pre-negotiated options for scale-up. Fourth, prioritize vendors with demonstrated regulatory experience in complex modalities and biomarker-driven trials to minimize downstream compliance risk. Fifth, consider regional capacity strategies that combine local inventory control with strategic global partners to mitigate tariff and logistics exposure.

Finally, cultivate internal capabilities for rapid technology assessment and vendor qualification, including structured scorecards that evaluate scientific rigor, data governance, quality systems, and cost transparency. By combining operational discipline with strategic partnership design, organizations can convert outsourcing from a transactional expense into a competitive advantage that accelerates discovery while managing risk.

Rigorous mixed-methods research approach combining executive interviews, secondary technical review, capability mapping, and scenario analysis to produce actionable intelligence

The research underpinning this summary combined qualitative and quantitative approaches to ensure robust, defensible insights. Primary research included structured interviews with senior R&D executives, procurement leaders, and technical heads across sponsor organizations and service providers to capture first-hand perspectives on capability requirements, vendor selection criteria, and regional operational constraints. These interviews were complemented by expert consultations with regulatory affairs professionals and supply chain specialists to contextualize policy and logistics impacts.

Secondary research incorporated published scientific literature, regulatory guidance, company disclosures, patent landscapes, and technology white papers to triangulate trends in assay platforms, computational adoption, and modality-specific development practices. Data synthesis emphasized validation across multiple sources to minimize bias and ensure that conclusions reflect convergent evidence rather than single-source assumptions.

Analytical methods included capability mapping against the segmentation schema and scenario analysis to explore how tariffs, supply disruptions, and technological adoption alter risk profiles. The methodology prioritized transparency in assumptions and used iterative review cycles with domain experts to refine interpretation and recommendations. Throughout, emphasis was placed on actionable insights that stakeholders can apply to procurement strategy, partnership design, and operational planning.

Concise conclusion emphasizing the necessity of scientific rigor, integrated data systems, and strategic risk management for successful outsourced discovery programs

In summary, the drug discovery outsourcing landscape is maturing into a more integrated, data-driven ecosystem where strategic partnership choices materially affect program velocity and scientific outcomes. Advances in computational chemistry, automated assay systems, and data integration technologies are elevating the importance of providers that can deliver reproducible, interpretable datasets and translate those outputs into defined experimental next steps.

Concurrently, policy developments and supply chain pressures have highlighted the need for diversified sourcing strategies and regional operational planning. Sponsors that proactively qualify alternative suppliers, rationalize inventory strategies, and negotiate adaptive contracting terms will be better positioned to sustain discovery momentum during periods of external disruption. Company differentiation is rooted in the capacity to combine deep technical expertise with transparent quality and data governance practices that support regulatory engagement and program scalability.

Ultimately, successful outsourcing in the current era requires a balance of scientific rigor, technological integration, and pragmatic risk management. Organizations that align their partner ecosystem to these principles can accelerate discovery, reduce avoidable delays, and create more predictable pathways from hypothesis to candidate selection.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Discovery Outsourcing Market, by Service Type

  • 8.1. Biological Services
    • 8.1.1. Assay Development
    • 8.1.2. Biological Testing
  • 8.2. Chemical Services
    • 8.2.1. Custom Synthesis
    • 8.2.2. Process R&D
  • 8.3. Data Management Services
    • 8.3.1. Bioinformatics
    • 8.3.2. Data Integration

9. Drug Discovery Outsourcing Market, by Discovery Phase

  • 9.1. Lead Optimization
    • 9.1.1. Compound Screening
    • 9.1.2. Structure-Based Drug Design
  • 9.2. Target Identification
    • 9.2.1. Biomarker Discovery
    • 9.2.2. Genomic Sequencing Methods

10. Drug Discovery Outsourcing Market, by Workflow

  • 10.1. Lead Identification & Candidate Optimization
  • 10.2. Preclinical Development
  • 10.3. Target Identification & Screening
  • 10.4. Target Validation & Functional Informatics

11. Drug Discovery Outsourcing Market, by Drug Type

  • 11.1. Large Molecules
    • 11.1.1. Biologics
    • 11.1.2. Biosimillar
  • 11.2. Small Molecules

12. Drug Discovery Outsourcing Market, by Application Area

  • 12.1. Cardiovascular Diseases
    • 12.1.1. Heart Failure
    • 12.1.2. Hypertension
  • 12.2. Infectious Diseases
    • 12.2.1. Bacterial Infections
    • 12.2.2. Viral Infections
  • 12.3. Oncology
    • 12.3.1. Hematological Malignancies
    • 12.3.2. Solid Tumors

13. Drug Discovery Outsourcing Market, by End User

  • 13.1. Contract Research Organizations
    • 13.1.1. Full-Service CROs
    • 13.1.2. Specialty CROs
  • 13.2. Pharmaceutical & Biotechnology Companies
    • 13.2.1. Large Enterprises
    • 13.2.2. SMEs
  • 13.3. Research Institutes
    • 13.3.1. Academic Institutions
    • 13.3.2. Government Research Centers

14. Drug Discovery Outsourcing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Drug Discovery Outsourcing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Drug Discovery Outsourcing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Drug Discovery Outsourcing Market

18. China Drug Discovery Outsourcing Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Agilent Technologies Inc.
  • 19.6. Aragen Life Sciences Ltd.
  • 19.7. BPS Bioscience, Inc.
  • 19.8. Celentyx Ltd.
  • 19.9. Charles River Laboratories International, Inc.
  • 19.10. Covance, Inc.
  • 19.11. Crown Bioscience, Inc.
  • 19.12. Curia Global, Inc.
  • 19.13. Dalton Pharma Services
  • 19.14. Eurofins Scientific
  • 19.15. Evotec SE
  • 19.16. Explicyte
  • 19.17. GenScript Biotech Corporation
  • 19.18. HD Biosciences Co., Ltd.
  • 19.19. IQVIA
  • 19.20. Jubilant Biosys Ltd.
  • 19.21. Laboratory Corporation of America Holdings
  • 19.22. Merck & Co., Inc.
  • 19.23. Oncodesign Services
  • 19.24. Personalis, Inc.
  • 19.25. Pfizer Inc.
  • 19.26. PPD Inc.
  • 19.27. Promega Corporation
  • 19.28. Revvity Discovery Limited
  • 19.29. Sanofi S.A.
  • 19.30. STC Biologics Inc.
  • 19.31. Syngene International Ltd.
  • 19.32. TCG Lifesciences Pvt. Limited
  • 19.33. Thermo Fisher Scientific Inc.
  • 19.34. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ASSAY DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ASSAY DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ASSAY DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CUSTOM SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CUSTOM SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CUSTOM SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROCESS R&D, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROCESS R&D, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROCESS R&D, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA INTEGRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA INTEGRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA INTEGRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COMPOUND SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COMPOUND SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COMPOUND SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STRUCTURE-BASED DRUG DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STRUCTURE-BASED DRUG DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STRUCTURE-BASED DRUG DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GENOMIC SEQUENCING METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GENOMIC SEQUENCING METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GENOMIC SEQUENCING METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD IDENTIFICATION & CANDIDATE OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD IDENTIFICATION & CANDIDATE OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD IDENTIFICATION & CANDIDATE OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION & SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION & SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION & SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET VALIDATION & FUNCTIONAL INFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET VALIDATION & FUNCTIONAL INFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET VALIDATION & FUNCTIONAL INFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOSIMILLAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOSIMILLAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOSIMILLAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY FULL-SERVICE CROS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY FULL-SERVICE CROS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY FULL-SERVICE CROS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SPECIALTY CROS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SPECIALTY CROS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SPECIALTY CROS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE ENTERPRISES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE ENTERPRISES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE ENTERPRISES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292.